PT - JOURNAL ARTICLE AU - Stefanelli, Paola AU - Trentini, Filippo AU - Petrone, Daniele AU - Mammone, Alessia AU - Ambrosio, Luigina AU - Manica, Mattia AU - Guzzetta, Giorgio AU - d’Andrea, Valeria AU - Marziano, Valentina AU - Zardini, Agnese AU - Grane, Carla Molina AU - Ajelli, Marco AU - Di Martino, Angela AU - Riccardo, Flavia AU - Bella, Antonino AU - Schepisi, Monica Sane AU - Maraglino, Francesco AU - Poletti, Piero AU - Palamara, Anna Teresa AU - Brusaferro, Silvio AU - Rezza, Giovanni AU - Pezzotti, Patrizio AU - Merler, Stefano AU - , AU - , TI - Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 - January 2022 AID - 10.1101/2022.01.27.22269949 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.27.22269949 4099 - http://medrxiv.org/content/early/2022/01/29/2022.01.27.22269949.short 4100 - http://medrxiv.org/content/early/2022/01/29/2022.01.27.22269949.full AB - The SARS-CoV-2 variant of concern Omicron was first detected in Italy in November 2021. Data from three genomic surveys conducted in Italy between December 2021 and January 2022 suggest that Omicron became dominant in less than one month (prevalence on January 3: 78.6%-83.8%) with a doubling time of 2.7–3.1 days. The mean net reproduction number rose from about 1.15 in absence of Omicron to a peak of 1.83 for symptomatic cases and 1.33 for hospitalized cases, while it remained stable for critical cases.Competing Interest StatementMarco Ajelli has received consultancy fees from Seqirus. None of those research funding is related to COVID-19. All other authors declare no competing interests.Funding StatementThis study was funded by EU grant 874850 MOOD (catalogued as MOOD 020), Fondazione Valorizzazione Ricerca Trentina (VRT) and project COVIDVAX.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Istituto Superiore di Sanita' obtained an ethical approval from its IRB (https://www.iss.it/comitato-etico) for sequencing SARS-CoV-2 genomes on clinical samples (ref. PRE BIO CE n.26259, July 29, 2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors